201. Genetic and Lineage Classification of Glioma-Initiating Cells Identifies a Clinically Relevant Glioblastoma Model
- Author
-
Haruo Nakayama, Satoshi Fujita, Takatoshi Sakurai, Kazuya Aoki, Ryo Suzuki, Sho Sato, Nozomi Hirai, Satoshi Iwabuchi, Yu Hiramoto, Norihiko Saito, and Morito Hayashi
- Subjects
0301 basic medicine ,Cancer Research ,Cell ,The Cancer Genome Atlas ,Computational biology ,Biology ,lcsh:RC254-282 ,Article ,03 medical and health sciences ,0302 clinical medicine ,Glioma ,medicine ,molecular classification ,Drug discovery ,Mesenchymal stem cell ,glioblastoma ,Wnt signaling pathway ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Phenotype ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Signal transduction ,Neural development ,glioma initiating cell - Abstract
The Cancer Genome Atlas (TCGA) project described a robust gene expression-based molecular classification of glioblastoma (GBM), but the functional and biological significance of the subclasses has not been determined. The present comprehensive analysis of 25 glioma-initiating cell (GIC) lines classifies GIC lines into four subtypes (classical, mesenchymal, proneural, and neural) that are closely related to the TCGA GBM subclasses and display distinct lineage characteristics and differentiation behavior that recapitulate neural development. More importantly, the GIC subtypes exhibit distinct biological phenotypes in relation to self-renewal capacity, proliferation, invasiveness, and angiogenic potential in vitro and in vivo. In addition, the GIC subtypes exhibit divergent patterns of signaling pathway activation and deactivation of the Wnt, Notch, and TGF-&beta, pathways. These results will improve drug discovery targeting certain genetic mutation in glioblastoma and improve the development of precision medicine.
- Published
- 2019